← writing

Can Pharma Brands Claim a ChatGPT Business Page?

·
aeomartech

Short answer, as of November 16, 2026: prescription brands can't use Business Agents, product feeds, or ChatGPT ads. OpenAI hasn't said whether a pharma company or an Rx brand can claim a profile. If one can, everything on it is brand-controlled copy and goes through MLR like any other promotional piece.

OpenAI launched Businesses in ChatGPT in beta on November 10. Through Business Hub, companies can claim a profile, keep their information current, and see how often ChatGPT mentions them and how many people click through. Eligible U.S. ecommerce and online-service businesses can also publish a Business Agent, a branded chat that sits apart from ChatGPT's own answers.

The question I keep getting is whether a pharma company, or one of its prescription brands, can take part. Some of that is settled. The part people care about most is still open.

What's off the table for Rx

Business Agents, product feeds, and ads are out. OpenAI's commerce policies exclude "prescription-only medications or medical products" from shopping experiences and feeds. Business Agents are limited to eligible U.S. ecommerce and online-service businesses, verification alone doesn't make you eligible, and an agent can't give advice that requires a professional license. ChatGPT ads list prescription medicines as not allowed.

A claimed profile won't buy better placement either. OpenAI's help center says claiming "doesn't guarantee increased visibility," and that advertising doesn't influence ChatGPT's independent answers. What a profile does offer is measurement: 28-day mention and click counts, plus discovery topics. For an online business, a mention counts only when ChatGPT references the website, not when it names the brand alone.

What OpenAI hasn't said

Whether a pharmaceutical company, or a prescription brand, can claim a profile. Eligibility "depends on factors including industry, location, and our verification and integrity checks." The profile policy adds that OpenAI may "hold off on allowing businesses in other categories to create or claim profiles until we have the safeguards needed." OpenAI is keeping the option to delay some categories, and it hasn't said whether pharma is one of them.

Treat the company and the brand as separate questions. OpenAI manages each distinct brand separately, and claiming a parent brand doesn't claim the others. A corporate profile for the manufacturer, if allowed, settles nothing for each Rx brand.

OpenAI also says existing Enterprise customers and advertisers can claim through their OpenAI representative. If your company already has ChatGPT Enterprise, ask that rep directly. A written answer is worth more than anything you'll infer from the beta docs.

Your profile may already exist

Profiles can be built from information OpenAI pulls from other sources, and OpenAI doesn't verify every detail. For most pharma teams, the more urgent question is what the unclaimed version says about them right now. Search for your company and each brand in ChatGPT and keep screenshots of what comes back. That's your baseline, and it's evidence if something on it is off-label.

If a claim is allowed, MLR still applies

Anything you write on a claimed profile is brand-controlled copy. For a prescription brand, that's promotional labeling. It needs fair balance and the ISI, and it belongs on your Form FDA 2253 submission at first use, the same as a new brand site page. A corporate profile is lower risk, though one product name in the description can change that.

Two setup details matter for review. If you create a new profile through Persona identity verification, "approval automatically publishes the profile," so there's no draft stage for MLR to look at. And once a profile is published, OpenAI Support "is unable to delete, unpublish, or hide" it. Get legal and MLR to approve the exact copy before anyone starts the claim.

There's also a pharmacovigilance wrinkle for any company that eventually qualifies for an agent, whether that's consumer health, devices, or Rx after a policy change. OpenAI says it doesn't share individual Business Agent conversations with businesses. If a patient reports an adverse event to your branded agent, you may have no way to see it. Bring your safety team in before anyone signs up.

What I'd do now

  1. Keep working on AI visibility without a profile. ChatGPT already talks about your brands, and mentions are counted when your website is cited. Treat the brand site as AEO work: clear, on-label answers in page copy, not buried in PDFs, so the model has something accurate to cite.
  2. Baseline the unclaimed profiles for the company and each brand, and check again monthly.
  3. If you have an OpenAI Enterprise relationship, put the eligibility question to your rep in writing, for the corporate entity and for each brand.
  4. Measure what you can today. ChatGPT referrals already show up in GA4 with chatgpt.com as the source. If you later claim a profile, reconcile Business Hub click counts against those sessions before you report either number upward.
  5. If a corporate claim becomes possible, have MLR-approved profile text ready so the claim doesn't stall in review or go live unreviewed.

Don't assume an Rx brand page, an agent, or a product feed is coming. And don't expect a claim to fix how the model describes your drug. That still depends on what you publish and what else the model finds.

This is a beta product and OpenAI's policies are changing quickly. I'll update this post as eligibility for pharma becomes clearer.

Working on AI search, measurement, or content inside a pharma or healthcare team? That's what I do at PharmaForward.

machine-readable: markdown · rss · llms.txt
open in: chatgpt · claude · perplexity
more writing ↗